Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo

Generated: June 24, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,966,768

« Back to Dashboard

Summary for Patent: 4,966,768
Title: Sustained release etodolac
Abstract:A sustained release dosage form of etodolac is provided which is a tablet having as essential components etodolac, hydroxyproplymethylcellulose, ethylcellulose and a release rate modifying agent such as dibasic sodium phosphate, the hydroxyproplymethylcellulose having a hydroxypropoxyl content of about 7.0% to 8.6% by weight.
Inventor(s): Michelucci; John J. (Plattsburgh, NY), Sherman; Deborah M. (Plattsburgh, NY), DeNeale; Richard J. (Willsboro, NY)
Assignee: American Home Products Corporation (New York, NY)
Application Number:07/268,646
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 4,966,768
Patent Claims: 1. A sustained release dosage form useful in providing once-a-day medication which consists essentially of an admixture of a carrier base material with etodolac and a release rate modifying agent and shaped and compressed to a solid unit dosage form having a regular and prolonged release pattern upon administration, the carrier base material comprising about 18 to 30 weight percent of the solid dosage form and being hydroxypropylmethylcellulose in admixture with 15 to 28 weight percent of the admixture of ethylcellulose, wherein the hydroxypropylmethylcellulose has a hydroxypropoxyl content of about 7.0 to about 8.6 weight percent, a methoxyl content of about 19-24 weight percent, a 2% aqueous solution viscosity of 80 to 120 cps, and an average molecular weight of less than 50,000, the release rate modifying agent being an effective amount of a physiologically acceptable buffer acid, buffer acid salt or mixture thereof.

2. The composition according to claim 1 wherein the release rate modifying agent is dibasic sodium phosphate.

3. The composition of claim 1 wherein the carrier base material is within the range of about 18% to about 30% by weight of the solid unit dosage form.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.